This one's been absolutely pummeled in the last couple months down from the 200s to the low 150s now. It’s rare to see BDX drop this hard, but I think the market’s starting to price in more pessimism than is actually warranted. The setup here is interesting if you have some patience and aren’t expecting fireworks overnight.

BDX is still a core medical devices player with diversified revenue streams across diagnostics, medication management, and biosciences. Even with cost pressures, their hospital contracts and consumables remain sticky. I’m seeing a lot of concern over margin compression lately, especially after their recent guidance cut, but the underlying demand drivers aging demographics, recurring supply contracts, and a backlog that’s still clearing from last year are all intact. That’s not the kind of thing that just evaporates because a couple quarters go sideways.

Granted, the risk here is that management has a tendency to sandbag and then under-deliver, so a second guidance cut would hammer the shares further. But if you go back and look at the last few years, BDX has usually managed to stabilize margins after big resets. If they can put up even a modest beat on next quarter’s operating margins, I think we’ll see a relief rally. The next earnings print is the big catalyst, and if supply chain and margin trends show improvement, the rerating could be sharp.

I’m targeting 177.05 in the next 10 weeks. No need to get greedy, just betting on mean reversion and a little operational execution. Not a moonshot, but a solid risk/reward if you want some defensive healthcare exposure while the market’s jittery elsewhere.